Weekly reads: cell and gene therapy deregulation, axed grant database, H3.3 in mESCs, remembering James Till
It’s been a crazy week on the cell and gene therapy front. We live in strange times more generally. I just wrote about a Thursday FDA cell and gene therapy roundtable that generally promoted the idea of less oversight. And far more speed to human use. RFK Jr. was present at the end and spoke. […]